Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study

  title={Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study},
  author={Simon L Hill and Javad Najafi and Michael P. Dunn and Paul Acheampong and Ashraf Kamour and Johann Grundlingh and Peter G. Blain and Simon H L Thomas},
  journal={Clinical Toxicology},
  pages={638 - 643}
Abstract Context: Recreational use of Synthetic Cannabinoid Receptors Agonists (SCRAs) has become increasingly common in many countries and may cause severe toxic effects. Objective: To describe the clinical features of toxicity in seven men after analytically confirmed exposure to MDMB-CHMICA, a recently described indole-based SCRA. Materials and methods: Clinical information and biological samples (blood, urine) were collected from patients with severe toxicity after suspected use of novel… 
Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015
Synthetic cannabinoid receptor agonists were found in 10% of this cohort with acute recreational drug toxicity but self-reported in only half of these, which suggests that presentations to the ED with acute synthetic cannabinoids receptor agonist toxicity may be more common than reported.
Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine. A report from the Identification of Novel psychoActive substances (IONA) study
Use of the New Psychoactive Substance (NPS) methiopropamine was first reported in 2011, but there are limited data on its acute toxicity.
Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA
The valine derivative AB-CHMINACA and the tert-leucine derivative MDMB-CHMICA (“third generation of SCs”) seem to be associated with more severe clinical toxicity than was previously reported in patients exposed to earlier generation SCs such as JWH-018.
Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project
The association with severe adverse reactions in nine acute analytically confirmed intoxication cases involving MDMB-CHMICA is consistent with other reports of serious toxicity linked to this substance, suggesting thatMDMB- CHMICA might be a particularly harmful SC.
Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification.
A toxicovigilance system for NPS is described that predicted the emergence of misuse of indole and indazole carboxylate SCRA, documented associated clinical harms, and notified relevant agencies.
Synthetic cannabinoids (SC)
Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication
It was concluded from femoral blood analysis that the 27-year-old man found dead after falling from the 24th floor of a high-rise building was under the influence of the synthetic cannabinoid MDMB-CHMICA, THC, amphetamine and MDMA.
Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist
The clinical course of three patients admitted under care from a local prison who were poisoned with MDMB-CHMICA are reported; all three patients developed hypercapnia, two had a reduced level of consciousness, two suffered seizures, and one was profoundly bradycardic (though propranolol was also detected on his drug screen).
Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples.
In this study, the in vivo phase I metabolism of MDMB-CHMICA was investigated using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) techniques and intrinsic activity of MDMICA at the CB1 receptor was determined applying a cAMP accumulation assay and showed that the compound is a potent full agonist.


Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service
Enquiries about SCRA-related toxicity have become increasingly frequent in the UK in spite of legal controls and commonly involve younger males, and differences in the patterns of toxicity associated with different branded preparations may occur.
Fatal intoxication with synthetic cannabinoid MDMB-CHMICA.
A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment
To identify systematically the scientific reports of adverse events associated with the consumption of SCs in the medical literature and poison centre data, this work searched online databases and manually searched reference lists up to December 2014 to identify eligible studies.
Central effects of the cannabinoid receptor agonist WIN55212‐2 on respiratory and cardiovascular regulation in anaesthetised rats
Results show that activation of CB1 cannabinoid receptors in the brain stem depresses respiration and enhances sympathetic tone and cardiac vagal tone and Opioid mechanisms are not involved in these central cannabinoid effects.
Synthetic Cannabinoid-Related Illnesses and Deaths.
Use of synthetic cannabinoids (SCs) in the United States is increasing, as are clusters of cases of serious adverse health effects, including death. Though SC intoxication can be difficult to
Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA.
Hospitalisation from synthetic cannabinoid MMB CHMINACA [Internet]; 2015 [cited 2016 May 5]. Available from: CHMINACA-MDMB-CHMICA-alert.pdf
  • 2015
Hospitalisation from synthetic cannabinoid MMB CHMINACA
  • 2015